Hannah Fabikan

Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non–Small Cell Lung Cancer

Lucian Beer, Maximilian J. Hochmair, Alexander Haug et al. · Clinical Nuclear Medicine · 2019 · 63 citations

Medicine, Oncology, Immunotherapy +16

Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer

Eva Obermayr, Christiane Agreiter, Eva Schuster et al. · Cells · 2019 · 44 citations · Full text

Medicine, Cancer Biology, Oncology +17

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Oliver Illini, Maximilian J. Hochmair, Hannah Fabikan et al. · Therapeutic Advances in Medical Oncology · 2021 · 44 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

Maximilian J. Hochmair, Hannah Fabikan, Oliver Illini et al. · Pharmaceuticals · 2020 · 30 citations · Full text

Medicine, Oncology, Pharmacology +15

Real-world experience with capmatinib in <i>MET</i> exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

Oliver Illini, Hannah Fabikan, Aurélie Swalduz et al. · Therapeutic Advances in Medical Oncology · 2022 · 29 citations · Full text

Medicine, Oncology, Pharmacology +17